LOGIN  |  REGISTER
Recursion
Terns Pharmaceuticals

Modivcare Appoints New Chief Commercial Officer and Chief Strategy and Innovation Officer

January 17, 2024 | Last Trade: US$11.13 0.24 2.20

DENVER / Jan 17, 2024 / Business Wire / Modivcare Inc. (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced the appointment of Jeff Bennett as Chief Strategy and Innovation Officer and Seth Ravine as Chief Commercial Officer, effective December 2023.

“I am incredibly excited for the appointment of these two positions, underscoring our commitment to building a top-notch leadership team that will steer Modivcare’s strategic course and drive success in this dynamic landscape,” said Heath Sampson, President and CEO of Modivcare. “The addition of Jeff and Seth’s roles reinforce our dedication to providing innovative and cohesive healthcare solutions with an enterprise mindset.”

“I am thrilled to be a part of the Modivcare team and contribute to the continued success of our organization,” said Jeff Bennett. “My focus lies in crafting our strategic framework to seamlessly blend digital and personal engagement to empower individuals in their care. By combining our solutions, we aim to leverage technology to deliver supportive care services to the community at scale. Together, we will navigate the ever-changing healthcare landscape, ensuring the continued empowerment of lives through compassionate, accessible, and comprehensive care.”

Jeff joined Modivcare in April 2023 through the acquisition of Higi. He previously served as the CEO of Higi, a consumer health engagement company. With nearly 30 years of experience, Jeff brings a wealth of knowledge and a proven track record of success to the team. Since his arrival, Jeff has already made a significant impact with his passion for innovative healthcare solutions. Jeff holds a Bachelor of Science in Mechanical Engineering from Purdue University and a Master of Business Administration from the Kellogg Business School at Northwestern.

“I am honored to assume the role of Chief Commercial Officer and play a key role in advancing Modivcare’s strategic expansion to reach markets where our presence is crucial,” said Seth Ravine. “Our commitment to delivering innovative solutions to our members is all about simplifying the experience of living with complex care needs, removing access barriers, and keeping our members thriving in the comfort of their homes. I am eager to continue collaborating with the talented teams across Modivcare to make a meaningful difference in the healthcare sector.”

Seth joined Modivcare in September 2021 as the Senior Vice President of Strategic Solutions through the acquisition of VRI. With over 25 years of sales experience, Seth has a proven track record of driving innovation and expanding market presence. In his expanded role, Seth will oversee the cross-functional Mobility, Home, and innovation strategy to drive progression in the industry and stimulate growth in untapped markets. Seth holds a bachelor’s degree from the University of Vermont.

About Modivcare

Modivcare Inc. (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their members. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal care and remote patient monitoring. To learn more about Modivcare, please visit www.modivcare.com.

Viking Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB